Sema Misir1*
Serap Ozer Yaman2,3
Ceylan Hepokur1
Osman Akidan4
Yuksel Aliyazicioglu3
Francisco J. Enguita5
Mazhar Salim Al Zoubi6- 1Department of Biochemistry, Faculty of Pharmacy, Sivas Cumhuriyet University, Sivas, Türkiye
- 2Department of Medical Biochemistry, Trabzon Kanuni Health Practice and Research Hospital, Trabzon Faculty of Medicine, University of Health Sciences, Trabzon, Türkiye
- 3Department of Medical Biochemistry, Faculty of Medicine, Karadeniz Technical University, Trabzon, Türkiye
- 4Department of Hematology, Mengücek Gazi Education and Research Hospital, Erzincan, Türkiye
- 5Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
- 6Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid, Jordan
A Corrigendum on
Identification of miR-342-5p/MDM4/p53 network in acute myeloid leukemia
by Misir S, Ozer Yaman S, Hepokur C, Akidan O, Aliyazicioglu Y, Enguita FJ and Al Zoubi MS (2024). Front. Cell. Death 3:1503241. doi: 10.3389/fceld.2024.1503241
In the published article, there was an error in the legend for Figures 2, 3 as published. The legends for Figures 2, 3 were placed in the wrong order. The legend for Figure 2 should be Figure 3, and the legend for Figure 3 should be Figure 2. The corrected legend appears below.
“FIGURE 2 | Prediction of miRNA targets from miRDB in HL-60 and KG-1 cells. (A) There are 119 predicted targets for hsa-miR-342–5p with expression level ≥5 in cell line HL-60. (B) There are 141 predicted targets for hsa-miR-342–5p with expression level ≥5 in cell line KG-1. In addition, thosewith a target scoregreater than 50 in all cells were selected. miR-342–5p and putative mRNAs and visualized using by Cytoscape software 3.8.”
“FIGURE 3 | (A) Receiver operating characteristic curve analysis of miR-342–5p expression levels in control and AML groups was determined using data from GSE51908. (B) The Kaplan–Meier survival curve of AML and Control groups. Survival analysis was performed using data from Bullinger et al. (2010).”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: acute myeloid leukemia, biomarkers, bioinformatics, non-coding RNAs, miRNA
Citation: Misir S, Yaman SO, Hepokur C, Akidan O, Aliyazicioglu Y, Enguita FJ and Al Zoubi MS (2025) Corrigendum: Identification of miR-342-5p/MDM4/p53 network in acute myeloid leukemia. Front. Cell Death 4:1592636. doi: 10.3389/fceld.2025.1592636
Received: 12 March 2025; Accepted: 07 April 2025;
Published: 25 April 2025.
Edited and reviewed by:
Olivier Micheau, Institut National de la Santé et de la Recherche Médicale (INSERM), FranceCopyright © 2025 Misir, Yaman, Hepokur, Akidan, Aliyazicioglu, Enguita and Al Zoubi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Sema Misir, c21pc2lyQGN1bWh1cml5ZXQuZWR1LnRy